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The abscopal effect describes the ability of locally administered radiotherapy to induce systemic antitu-
mor effects. Over the past 40 years, reports on the abscopal effect following conventional radiation have
been relatively rare, especially in less immunogenic tumors such as lung cancer. However, with the con-
tinued development and use of immunotherapy, reports on the abscopal effect have become increasingly
frequent during the last decade. Here, we present three illustrative case reports from our own institution
and previous published cases of the abscopal effect in patients with non-small cell lung cancer, treated
with immune checkpoint inhibitors and radiotherapy. We also present a concise review of the clinical and
experimental literature on the abscopal effect in non-small cell lung cancer.
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The abscopal (ab- ‘position away from’ and scopus ‘target’) effect is a rare phenomenon in radiotherapy characterized
by tumor regression outside the irradiated volume. It was first described by Mole in 1953 and has since been observed
in different types of cancers after radiotherapy directed at the primary tumor or metastases [1]. A recent systematic
review of 46 case reports of the abscopal effect following radiotherapy noted that the majority of cases occurred
in immunogenic tumors such as renal cell carcinoma, melanoma, lymphoma and hepatocellular carcinoma [2].
Although the abscopal effect has been described in patients with non-small-cell lung cancer (NSCLC) treated only
with radiotherapy [3,4], this event seems to be rare due to the low immunogenicity of NSCLC and immunotolerance
at the tumor site [5].
However, the effect is thought to occur with greater frequency when radiation is combined with immunostim-
ulating agents such as immune checkpoint inhibitors [6,7]. With increased use of immunotherapy in addition to
radiotherapy in lung cancer treatment, the abscopal effect is expected to become more common. In a recent system-
atic review, Chicas-Sett et al. investigated the efficacy and safety of stereotactic body radiation therapy (SBRT) and
checkpoint inhibitor combination therapy in patients with lung cancer. They concluded that these two treatments
combined present a good safety profile and achieve high rates of local control and greater chances of obtaining
abscopal responses than radiotherapy alone [8].
Since lung cancer has a high prevalence, and immunotherapy is used in an increasing proportion of patients
and radiotherapy is often given for symptomatic and prognostic reasons, we first provide a concise overview of
immunotherapy and radiotherapy in lung cancer. We then present three case reports from the Lungenfachklinik
Immenhausen (Immenhausen, Germany) demonstrating the abscopal effect in patients with metastatic lung cancer
treated with radiotherapy and immunotherapy. We also present the results of 11 previous clinical cases identified
through a systematic literature search. Finally, we summarize the molecular effects of radiotherapy in the tumor
microenvironment, the immunological mechanism of the abscopal effect, the rationale for combining radiotherapy
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Table 1. Summary of three clinical cases showing abscopal effects observed at the Lungenfachklinik Immenhausen.
Case Lung cancer site Previous treatment Site of
radiotherapy
Site of abscopal
effect
Radiotherapy
dose
Immunotherapy
1 LCNEC of the right upper lobe
with adrenal metastases
(cT4N0M1b)
Pemetrexed, cisplatin and
bevacizumab; disease
progression after two cycles
Second and third
thoracic vertebrae
Adrenal glands 10 × 3 Gy Nivolumab
2 ADC of the left upper lobe with
brain and ocular metastases
(cT2N3M1c)
Nab-paclitaxel/carboplatin +
atezolizumab, then
atezolizumab; progression of
brain metastasis after 5 months
of treatment
Brain Lung and
mediastinal lymph
nodes
10 × 3 Gy Atezolizumab
3 ADC of the middle lobe with
malignant ipsilateral pleural
effusion (cT3N2M1a)
None Brain Lung and pleural
disease
10 × 3 Gy Pembrolizumab
ADC: Adenocarcinoma; LCNEC: Large-cell neuroendocrine carcinoma.
and immunotherapy, their applications in clinical trials exploring this important therapeutic option, and future
challenges. To the best of our knowledge, this is the first comprehensive review focusing on the abscopal effect in
patients with lung cancer.
Immunotherapy & radiotherapy in lung cancer
Immunotherapy in lung cancer
The use of immunotherapy in NSCLC is rapidly increasing. In particular, immune checkpoint inhibitors have
shown some promise in modulating the tumor microenvironment, in order to fight against the tumor’s attempt to
evade the immune system [9].
Ipilimumab is a monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) that blocks
the CTLA-4 inhibitory pathway and restores effective T-cell function. Ipilimumab was approved by the US FDA in
2011 for the treatment of metastatic melanoma but has so far not been approved for the treatment of lung cancer.
Antibodies acting on programmed cell death protein 1 (PD-1) and its ligand, programmed death ligand 1
(PD-L1), have gained increasing attention in the treatment of lung cancer. Nivolumab and pembrolizumab are
anti-PD-1 antibodies that bind and block PD-1 receptors on activated T-cells, while durvalumab and atezolizumab
are anti-PD-L1 antibodies targeting PD-L1 on tumor cells. PD-1/PD-L1 pathway blockage allows T cells to
destroy tumor cells [10]. To date, pembrolizumab, nivolumab and atezolizumab have received FDA approval for the
treatment of metastatic NSCLC, with PD-L1 expression as a selection criterion for treatment with pembrolizumab.
Durvalumab has recently been approved for the treatment of unresectable stage III NSCLC patients whose
disease has not progressed following platinum-based chemotherapy and radiation therapy [11].
Radiotherapy in lung cancer
Radiotherapy plays an important role in lung cancer treatment and it is used from early to advanced stages.
Currently, resection is the standard of care for early-stage NSCLC; however, SBRT can be the preferred treatment
for elderly or comorbid patients, resulting in local control rates of 90% at 5 years [12,13]. For locally advanced
disease, especially with extensive lymph node metastases, chemo-radiotherapy (concurrent or sequential) followed
by durvalumab has recently become the standard of care [14,15]. Radiotherapy is also used as a palliative treatment in
stage IV lung cancer [16], for example, as brain radiotherapy or radiotherapy of bone metastases causing pain or at
risk of instability. Radiotherapy has also demonstrated positive effects in oligometastatic disease [17]. These results
are supported by two recent Phase II trials demonstrating that stereotactic ablative radiotherapy is associated with
an improvement in overall survival in patients with oligometastatic cancers [18,19].
Case reports of abscopal effects in lung cancer
We present recent case reports of three clinical cases of the abscopal effect in patients with metastatic lung cancer
treated with radiotherapy and immunotherapy observed at the Lungenfachklinik Immenhausen (summarized in
Table 1).
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Localized
therapy
4 cycles first-line therapy
pemetrexed + cisplatin +
bevacizumab
Systemic
therapy
Sep 15th 2017
Hemilaminectomy Th3
Lung/
Th2/3
Adrenal
glands
Feb 2017
diagnosis
metastatic
LCNEC
Since May 11th 2017
second-line therapy with
nivolumab
Oct–Nov 2017
Radiation Th2/3
Feb 2017 May 2017 Aug 2017 Mar 2018 Jun 2018 Sep 2018
4 × pemetrexed/cisplatin/
bevacizumab
Progression Progression Progression
ProgressionProgressionProgression
Nivolumab
Remission
Abscopal remission
Figure 1. Case 1: thoracic and abdominal CT scans. Abscopal remission (arrows) of adrenal metastases after thoracic radiotherapy
performed in October–November 2017.
LCNEC: Large-cell neuroendocrine carcinoma; Th: Thoracic vertebrae.
Case 1
A 54-year-old male patient presented with a pulmonary large cell neuroendocrine carcinoma of the right upper
lobe, associated with bilateral adrenal metastases and a PD-L1 tumor proportion score of 20%. The tumor, node,
metastasis classification (8th edition [20]), based on positron emission tomography-CT and thoraco-abdominal
CT, was cT4N0M1b (adrenal). After four cycles of chemotherapy (pemetrexed, cisplatin and bevacizumab), CT
scans revealed disease progression in the right upper lobe as well as in both adrenal glands (Figure 1). Second-line
therapy with nivolumab was started, leading to minor progression according to Response Evaluation Criteria in
Solid Tumors 1.1 criteria, but with clinically progressive and increasingly symptomatic spinal cord compression
due to tumor invasion.
At this point, pseudoprogression was discussed as well. In our clinical experience, after evaluation of more than
150 cases of patients that have been treated with nivolumab as second-line therapy for NSCLC, we have not found
any patient with radiological pseudoprogression after 2 months. We routinely perform CT-scans after 7 and 14
weeks of therapy. Especially in this patient, we waited for a second CT-scan after 3 months to unequivocally rule
out pseudo-progression before initiating radiotherapy.
Hemilaminectomy of the third thoracic vertebra combined with resection of the epidural tumor mass was
performed leading to an R2 resection. Postoperative radiotherapy (30 Gy) was applied targeting the second and
third thoracic vertebrae. Nivolumab was halted only for resection and reintroduced shortly before the first dose of
radiation. CT scans 4 months after the first radiotherapy showed partial regression of the lung tumor and adrenal
metastases. The patient showed disease progression 10 months after radiotherapy but is still alive 25 months after
the initial diagnosis.
Case 2
A 64-year-old male patient presented with a central adenocarcinoma of the left upper lobe, considered cT2N3M1c
due to pathological mediastinal contralateral lymph nodes and distant metastases (brain and ocular). The pa-
tient’s PD-L1 results are currently blinded due to the requirements of a clinical trial (IMpower130 trial: Clin-
icalTrials. gov identifier NCT02367781). The radiological images after 5 months of treatment (four cycles of
nab-paclitaxel/carboplatin with atezolizumab followed by four cycles of atezolizumab alone) showed an excellent
response of the ocular metastasis, but progression of the brain metastasis (Figure 2). The thoracic tumor man-
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Jan 2017 March 2017 May 2017 Oct 2017 Jan 2019
July 2017
WBRTLocalized
therapy
Systemic
therapy
Lung/
mediastinum
Ocular
Brain
Nab-paclitaxel/carboplatin
+ atezolizumab Atezolizumab monotherapy
Remission
Remission
Stable
Minor progression
Stable remission
Progression
Abscopal remission
Complete remission
Remission
Ongoing remission
Ongoing remission
Ongoing remission
Figure 2. Case 2: CT scans. Abscopal remission (arrows) of thoracic disease after whole brain radiotherapy performed in July 2017.
ifestations showed partial remission after four cycles of combined chemotherapy and immunotherapy with no
further shrinkage after four additional cycles of atezolizumab monotherapy. Whole-brain radiotherapy (WBRT)
was performed and atezolizumab was continued. Radiological follow-up 4 months after WBRT showed a partial
response in the brain as well as complete remission of lung and mediastinal tumor masses. The patient is still alive
with radiologically nearly complete remission 28 months after the initial diagnosis of metastatic lung cancer.
Case 3
A 70-year-old male patient presented with a central adenocarcinoma of the middle lobe, associated with positive
mediastinal lymph nodes and malignant ipsilateral pleural effusion (cT3N2M1a). There were no EGFR or ALKmu-
tations and the PD-L1 tumor proportion score was 70%. First-line therapy with pembrolizumab was started, leading
to a partial response. After a year of treatment, pulmonary and pleural disease progression occurred and a clinically
symptomatic brain metastasis associated with perimetastatic cerebral edema appeared. Pembrolizumab was con-
tinued and WBRT added (30 Gy in ten fractions). Radiography of the thorax after radiotherapy showed partial
regression of the lung tumor and pleural effusion. A thorax CT scan was performed 2 months after WBRT. The
results in the 2-month follow-up CT scan are less evident when compared with the conventional chest x-ray images
2 weeks after radiotherapy, demonstrating that the initial effect was short lived (Figure 3). The patient is still alive
19 months after the initial diagnosis.
Previously published cases of abscopal effects in patients with lung cancer
Search strategy
We performed a systematic literature search for case reports and series of the abscopal effect following radiotherapy
in patients with NSCLC. The inclusion criteria for the published articles were documentation of: primary NSCLC,
site and dose of radiotherapy and site of the abscopal effect. Conference abstracts, editorials, reviews and cases not
fulfilling of the inclusion criteria were to be excluded.
The search was performed in PubMed using the terms: ‘abscopal AND lung’, ‘abscopal AND pulmonary’,
‘abscopal AND thoracic’, ‘nontargeted radiotherapy AND lung’, ‘nontargeted radiotherapy AND pulmonary’,
‘nontargeted radiotherapy AND thoracic’, ‘bystander AND lung’, ‘bystander AND pulmonary’ and ‘bystander
AND thoracic’. No limit concerning year of publication and language was used. The final search was performed in
May 2019.
In total, 1206 articles were identified from the PubMed search. After removal of 553 duplicates, the titles and
abstracts of the remaining 653 articles were assessed for inclusion; 24 articles were eligible. Of these 24 articles, 13
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Aug 2017 Dec 2017 Feb 2018 Aug 2018 Jan 22nd 2019 Apr 11th 2019
Jan 23rd 2019 Mar 6th 2019 Apr 11th 2019
Feb 11th to 25th 2019
WBRT
Localized
therapy
Systemic
therapy
Lung
Lymph node
position 7
Pleural
effusion
Pembrolizumab monotherapy
Remission Remission
Remission Remission
RemissionRemission
Remission
Pseudoprogression
Progression Abscopal remission
Ongoing remission
Ongoing remission
Figure 3. Case 3: CT scans and x-ray images. Abscopal remission (arrows) of lung and pleural disease after whole brain radiotherapy
performed in February 2019.
were further excluded: eight articles were reviews and did not include case reports, one article reported an abscopal
effect but the primary tumor was melanoma, one case report described an abscopal effect in liver nodules considered
to be hepatocellular carcinoma, two articles (including patients with NSCLC and small cell lung cancer) did not
clearly demonstrate an abscopal effect, and one prospective cohort study described the abscopal effect in NSCLC
but the site of response was not specified. Eleven articles fulfilled the primary search inclusion criteria (Figure 4).
Review of previous clinical cases
Table 2 presents a summary of the 11 case reports showing the abscopal effect in patients with lung cancer.
Rees and Ross reported the first case of a patient presenting with lung cancer and demonstrating an abscopal
effect with radiotherapy in 1983 [3]. The patient, with advanced adenocarcinoma of the left lower lobe with
multiple subcutaneous metastases, was treated with palliative radiation of the mediastinum and left lower lung
using parallel opposed beams and a total dose of 35 Gy at 3.5 Gy per fraction. During treatment, a mass reduction
was noticed in the subcutaneous metastases in the forehead and in the left shoulder which had not been treated
by radiotherapy. Furthermore, at the 2-week follow-up visit, the subcutaneous nodules were impalpable and a
maculo-papular erythema appeared on both irradiated and nonirradiated skin. One week later, there was already
evidence of regrowth of the left shoulder lesion and new subcutaneous metastases rapidly developed at other sites.
The forehead lesion reappeared shortly before the patient’s death 4 months after completion of radiation therapy [3].
Three studies showed an abscopal effect with radiotherapy alone in patients with NSCLC [4,21,22,28]. In 2013,
Siva et al. described the abscopal effect in adrenal and bone metastases after SBRT of the lung [4]. In 2018, Hamilton
et al. reported an abscopal effect in the lung after brain radiotherapy [21]. In 2019, Kuroda et al. reported the case
of an abscopal response in the lung after mediastinum radiotherapy [22].
The first case of the abscopal effect of radiotherapy associated with immunotherapy was reported by Golden et al.
in 2013, who combined radiotherapy with ipilimumab in a patient with metastatic adenocarcinoma of the lung [7].
The patient had progression after different lines of chemotherapy and previous lung radiation. Ipilimumab and
local radiotherapy to one of the hepatic metastases was initiated, with the intent to generate an abscopal response. It
is noteworthy that the authors report that this experimental approach was only based on two previous case reports
in melanoma patients. Radiotherapy to a total dose of 30 Gy distributed in five fractions was delivered over a period
of 10 days to the liver lesion, with one cycle of ipilimumab during radiation and three cycles afterward. Following
future science group www.futuremedicine.com 1449
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Figure 4. PRISMA flow diagram of the literature search strategy.
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Figure 5. Timeline of publications of the abscopal effect in non-small-cell lung cancer during the last four decades
(Table 2). The figure indicates a particular concentration within the last decade when radiotherapy is associated with
immunotherapy (green cases) versus radiotherapy alone (blue cases).
this treatment, chest CT and positron emission tomography-CT showed a dramatic tumor response, not only in
the radiotherapy field, but also at distant sites. The patient showed no evidence of disease at the 1-year follow-up [7].
More recent cases reported the abscopal effect in patients with lung cancer treated with radiotherapy and
immunotherapy, in particular with nivolumab [23–28]. These cases are very heterogeneous in terms of the site of
radiotherapy and abscopal effect, with abscopal responses described in the lung, brain or adrenal gland after bone,
liver or lung radiotherapy.
Reports about the abscopal effect in lung cancer have appeared regularly since 2013, next to a potential awareness
among clinicians that the introduction of immunotherapy seems to play a role in this phenomenon (Figure 5).
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Radiation & the immune system
The main focus of radiotherapy is the control and eradication of local tumor tissue by maximizing direct tumor cell
damage and minimizing healthy tissue impairment [29]. The main target of ionizing radiation is the DNA itself:
radiation induces base damage, single-strand breaks or double-strand breaks that may lead to cell death, especially
in the setting of defective repair mechanisms [30]. The toxic effect of radiation can equally affect surrounding
leukocytes, resulting in subsequent immunosuppression. Lymphopenia following radiotherapy for solid tumors such
as lung or breast cancer has been described [31,32]. This effect is mainly explained by the high radiation sensitivity
of lymphocytes (less than 1 Gy). It is noteworthy that the entire circulating blood pool receives a potentially
lymphotoxic dose during certain radiotherapy courses, for example, large volume thoracic radiotherapy [33].
More recently, radiotherapy has also been shown to induce a number of systemic immune-modulatory effects
in the tumor. Radiotherapy can contribute to creating an immunosuppressive environment by making T cells
dysfunctional and by recruiting immunosuppressive myeloid cells that directly promote tumor growth [34,35].
Radiotherapy might also induce PD-L1 expression in the tumor microenvironment, allowing engagement of
inhibitory PD-1 receptors on T-cells and inhibiting the T-cell antitumor response [36]. However, radiation may
generate positive immune-modulatory effects leading to beneficial tumor-specific immune responses [37]. The
abscopal effect is believed to arise from the local capacity of radiotherapy to stimulate this systemic immune
response to control unirradiated cancer. Demaria et al. were the first to identify an immune-mediated mechanism
as the basis of this effect and more recent studies have demonstrated how radiotherapy can activate a tumor-specific
systemic immune response [38–40]. Radiotherapy acts as an immune modulator in the tumor microenvironment
through several mechanisms that are summarized in Figure 6.
In particular, upregulation of the endoplasmic reticulum chaperone calreticulin and its translocation to the
plasma membrane of dying irradiated tumor cells facilitates phagocytosis of material from tumor cells via binding
to CD91 [41]. Heat shock proteins released from dying cells, such as HSP70, can bind to several receptors on
dendritic cells, including CD91 and Toll-like receptor 4 (TLR4), and provide danger signals that may not only
activate antitumor immune responses by CD8+ T cells but also by natural killer (NK) cells [42,43].
High-mobility group box 1 protein, released from dying tumor cells, binds to Toll-like receptor 4, leading to
dendritic cell maturation [44,45]. This factor also stimulates monocytes to produce cytokines such as TNF-α and
the interleukins IL-1, IL-6 and IL-8, acting as pro-inflammatory mediators, which also contribute to dendritic
cell maturation [46]. Moreover, dying tumor cells release ATP, which binds to purinergic receptors, including
P2RY2 and P2RX7, and promotes the infiltration of tumors with dendritic cells and subsequent inflammasome
activation and IL-1β secretion [47]. Radiotherapy also stimulates tumor cells to release the chemokines CXCL16 and
CXCL10, and increases the expression of adhesion molecules such as E-selectin, intercellular adhesion molecule 1
and vascular cell adhesion protein 1 on endothelial cells. Surviving irradiated cells increase the expression of death
receptors, including Fas, and upregulate major histocompatibility complex (MHC) class I molecules, improving
their recognition and killing by activated tumor antigen-specific CD8+ T cells [48–54]. Upregulation of ligands
of the activating NK receptor NKG2D on irradiated tumor cells enables them to deliver their co-stimulatory
signals to CD8+ T cells [55] and renders them susceptible to NK cells [56]. Activated dendritic cells migrate to
local lymph nodes where they cross-present tumor antigens on MHC class I molecules to naive CD8+ T cells.
Those with specificity for tumor antigens proliferate and differentiate into cytotoxic effector T-cells. These effector
T-cells migrate back to the tumor, attracted by chemokines released due to irradiation-induced cell destruction. In
addition, these effector T cells can induce tumor cell death in nonirradiated lesions distal to the initial irradiation
site [51,52]. The infiltration of tumors by effector T cells seems to be promoted by radiotherapy-induced remodeling
of the vascularization in the tumor microenvironment [57,58]. However, tumors still can escape an immune response
mediated by activated cytotoxic T cells by mechanisms that, in addition to the loss of tumor antigens or MHC
class I expression, also include the upregulation of PD-1 ligands, which can engage the inhibitory PD-1 receptor
on the effector T-cells and lead to T-cell exhaustion [59].
The dose per fraction of radiotherapy seems to have an important impact on systemic consequences. Radiation-
induced nuclear DNA release and subsequent sensing of cytoplasmic double-stranded DNA can activate the cyclic
guanosine monophosphate–adenosine monophosphate synthase (cGAS). This DNA sensor induces production of
the second messenger cyclic guanosine monophosphate–adenosine monophosphate (cGAMP), which binds and
activates the STING (stimulator of interferon genes) pathway, producing type I IFN, a key mediator of dendritic
cell recruitment and maturation [60–62]. Notably, the study of Vanpouille-Box et al. demonstrated that a radiation
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Figure 6. Mechanism of the abscopal effect and its relationship with immune checkpoint inhibitors. Radiotherapy
can lead to immunogenic cell death and the release of tumor antigens by irradiated tumor cells. These antigens are
taken up by professional antigen-presenting cells such as dendritic cells. Upon maturation, the dendritic cells migrate
to the lymph nodes where they present the processed antigens in the context of major histocompatibility complex
molecules to T cells. Activation of CD8+ T cells requires the cross-presentation of exogenous tumor antigens on major
histocompatibility complex class I molecules. Naive CD8+ T cells receive the antigen-specific signal through the T-cell
receptor and co-stimulatory signals such as CD80 and CD86 through CD28. Tumor antigen-specific CD8+ T cells
proliferate and differentiate into cytotoxic effector T cells that migrate from the lymph nodes to the tumor sites
(primary tumor and nonirradiated tumor metastases) in order to exercise their effect of killing tumor cells. However,
cytotoxic T-lymphocyte-associated antigen 4 binds to CD28 competitively with CD80/86 and inhibits the activation of
T cells. Following T-cell activation, programmed cell death protein 1 receptors are expressed on the T-cell surface,
which bind primarily to programmed death ligand 1 and inhibit the activity of the CD8+ T cells. Therefore, the
administration of immune checkpoint inhibitors (anti-cytotoxic T-lymphocyte-associated antigen 4, antiprogrammed
cell death protein 1 and anti-programmed death ligand 1) can enhance the antitumor immune response of
radiotherapy.
dose above a threshold of 10–12 Gy per fraction could attenuate the immunogenicity of cancer cells because of the
induced upregulation of the DNA exonuclease three-prime repair exonuclease 1. Three-prime repair exonuclease 1
degrades cytosolic double-stranded DNA, thereby removing the trigger for the cGAS–STING pathway, abrogating
the immunogenicity of irradiated cancer cells [63].
Although the abscopal effect of radiotherapy alone has been reported in a growing number of cases [2], the overall
occurrence rate is relatively low. This may be explained by the counterbalance of the pro-immunogenic effects
produced by ionizing radiation with the immunosuppressive consequences of radiotherapy.
Timing of immunotherapy in combination with radiotherapy
Theoretical principles
The combination of radiotherapy and checkpoint blockade can act at different stages of the antitumor immune
response. The release of new tumor antigens by radiotherapy may interact with anti-CTLA-4 to increase the
diversity of tumor antigen-specific naive T cells that become activated. At the same time, memory T cells with
specificity for tumor antigens might become reactivated. In addition, anti-CTLA-4 can inhibit the development
of regulatory T cells (Tregs), which promote tolerance against tumor antigens. Radiotherapy can increase the
infiltration of the activated or reactivated T-cells into the tumor. Anti-PD-1 and anti-PD-L1 help to prevent the
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suppression of effector T cells induced by upregulation of PD-L1 in tumors mediated by radiotherapy. Moreover,
anti-PD-1/PD-L1 can reactivate exhausted intratumoral T cells [64,65].
Preclinical evidence
Due to the different timing of these mechanisms in the immune response, it might be important to determine
the most effective sequence of radiotherapy and checkpoint inhibition. Theoretically, it would be expected that
radiotherapy and anti-CTLA-4 should follow in quite short order and that anti-PD-1/PD-L1 would be effective at
later time points. These concepts are largely supported by results of different pre-clinical models. In murine models
of breast cancer, concurrent and postradiotherapy treatment with anti-CTLA-4 has been shown to control tumor
growth, compared with monotherapy [6,66]. Other studies have reported an enhanced antitumor response from
combining radiotherapy with anti-CTLA-4, showing that this effect was principally due to a reduction of Tregs
and an increase of cytotoxic T-cell populations in both primary and secondary tumors [67,68]. Notably, treatment
with anti-CTLA-4 can be effective even before radiotherapy due to the depletion of Tregs [69].
Other studies have investigated the optimal timing of radiotherapy and anti-PD-1/PD-L1 combination. In two
different preclinical studies, Dovedi et al. showed how the administration of anti-PD-L1 at the same time point
as radiotherapy (i.e., at the beginning and at the end of radiotherapy) was superior to sequential treatment, which
might suggest that an upregulation of anti-PD-L1 occurs rapidly after radiotherapy. Interestingly, the mechanism
responsible of PD-L1 upregulation on tumor cells was reported to involve the production of IFN-γ by tumor-
infiltrating CD8+ T cells. This acquired resistance to radiotherapy could be avoided by concurrent administration
of anti-PD-L1 [70,71]. To define the best timing of anti-PD-1/L1 administration, a close look at the kinetics of
T-cell tumor infiltration following radiotherapy might be required. Hettich et al. reported that after radiotherapy
alone with 12 Gy over two consecutive days, the overall tumor-infiltrating lymphocyte (TIL) peak appeared 5 days
after radiotherapy and then gradually decrease to preradiotherapy levels. Almost all the TILs were CD8+ T cells,
while the number of CD4+ Tregs was low. Considering that PD-1 was strongly expressed on TILs from irradiated
tumors already on day 5 postirradiation, the authors administered anti-PD-1 on the day of the second radiotherapy
fraction. The radiotherapy/anti-PD-1 combination was highly synergistic, inducing substantial tumor regression
in five out of nine mice [72]. Recently, the combination of radiotherapy and anti-CTLA-4 or PD-1 blockade
has been evaluated in mouse models. Radiotherapy mainly enlarged the intratumoral T-cell receptor repertoire,
likely by increasing the amount and diversity of tumor antigens released from tumors and presented by dendritic
cells. Anti-CTLA-4 in combination with radiotherapy promoted the expansion of tumor antigen-specific T-cell
clones, while blockade of the PD-1/PD-L1 pathway was required to prevent exhaustion of activated effector T
cells [6]. Taken together, these studies suggest that, even if the precise T-cell tumor kinetics depend on the model
and radiotherapy dose, anti-PD-1 should be administered concurrently or shortly following radiotherapy to take
advantage of the peak in tumor effector CD8+ T cells [73].
Clinical evidence
Clinical case reports have found that the administration of anti-CTLA-4 before radiotherapy correlated with
improved survival in patients with metastatic melanoma [74,75].
Two Phase I trials have evaluated the delivery of ipilimumab after and before SBRT in patients with metastatic
melanoma [73,76]. Interestingly, ipilimumab administered after SBRT resulted in only an 18% partial response rate,
whereas administration of ipilimumab before radiotherapy showed a 50% complete or partial response rate and a
27% complete response rate [76]. At present, this treatment has not yet found its way into clinical practice. Currently,
different trials investigating the efficacy of radiotherapy in combination with immunotherapy are being finalized.
However, these studies seem to only marginally evaluate the optimal timing of radiotherapy. In our case reports
(Table 1), anti-PD-1 antibodies were administered before and continued during and after radiotherapy. Thus, at
present it seems difficult to determine the best treatment schedule for radiotherapy and immunotherapy. Moreover,
the timing of the antitumor immune responses that are ongoing is likely to be much more complex in patients than
in animal models so that it is difficult to apply directly preclinical evidence obtained in mouse models. In patients,
one may observe different phases of the immune response for different T cell clones at the same time point.
Interaction of nodal irradiation & the immune system
It is unclear which type of radiotherapy regimen should be used when radiotherapy is combined with immunother-
apy. It is also unknown whether elective nodal irradiation affects adaptive immune responses and the combinatorial
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efficacy of these two treatments. As shown in Figure 6, tumor-draining lymph nodes (TDLNs) are the main location
at which antigen-presenting cells prime T cells. The importance of TDLNs in the generation of a specific antitumor
immune response has been demonstrated by preclinical studies. Takeshima et al. showed that TDLN-deficient mice
and mice with surgically ablated TDLNs presented with reduced tumor control following radiotherapy [77]. In a
preclinical model, Marciscano et al. demonstrated that elective nodal irradiation decreased the immune response
and affected the combinatorial efficacy of SBRT with immunotherapy. They showed that radiotherapy-mediated
chemokine expression was attenuated by the irradiation of both the tumor and TDLNs, resulting in impaired
trafficking of CD8+ T cells into the tumor and reducing survival [78]. Clinical data has demonstrated that for most
cases elective nodal irradiation is not required and recent guidelines do not recommend this routinely [79], whether
this might affect potential abscopal effects in the future remains unclear.
Optimal dose & fractionation
Radiotherapy is traditionally delivered with 1.8–2.2 Gy per fraction (normofractionation); however, fewer fractions
of higher doses (hypofractionation) are common in the palliative or stereotactic setting, while hyperfractionation
is established in the primary treatment of small cell lung cancer [80]. The dose and fractionation seem to impact
the immunotherapeutic potential and the presence of an abscopal effect [81]. Considering that lymphocytes are
exquisitely sensitive to radiation, repetitive daily radiotherapy can deplete migrating immune effector cells. Frey
et al. showed that following 2 × 5 Gy fractions, the intratumoral CD8+ T-cell peak appeared at day 8 and declined
by day 9, and an increase of Tregs was seen following the infiltration of CD8+ T cells, at days 8–10. The optimal
timing to re-irradiate the tumor in this case would be at days 9–10 when the cytotoxic T-cells have already migrated
away and immunosuppressive Tregs are still inside the tumor [82]. Siva et al. demonstrated that single-dose (12 Gy)
radiotherapy did not deplete established immune effector cells (CD8+, CD4+ and NK cells) critical to the curative
activity of radiotherapy when associated with immunotherapy [83]. Indeed, compared with conventional modalities,
radiotherapy with ablative high dose per fractionation seems to be more effective in enhancing the antitumor
immune response [84]. Other studies have investigated the combination of hypofractionated radiotherapy and
immunotherapy. Dewan et al., for example, demonstrated in murine breast and colon cancer models that 5 × 6 Gy
and 3 × 8 Gy protocols of radiotherapy were more effective in inducing the immune-mediated abscopal effect than
a single ablative dose when combined with immunotherapy [66]. Similarly, the study of Schaue et al., on a murine
melanoma model, found that fractionated treatment with medium radiation doses of 7.5 Gy per fraction induced
the best tumor control and antitumor response [81].
The dose per fraction of radiotherapy seems to be correlated with the generation of immunological effects. As
previously reported, a radiation dose above a threshold of 10–12 Gy per fraction could abrogate the immunogenicity
of irradiated cancer cells, removing the trigger for the cGAS–STING pathway [63]. These considerations have
important clinical implications for dose selection and fraction when radiotherapy is associated with immunotherapy.
Optimal radiation dose, timing and fractioning remain points of debate and clear recommendations are still
lacking [85].
Clinical trials combining radiotherapy & immune checkpoint inhibitors
Various clinical trials have investigated the efficacy and safety of combining radiotherapy and checkpoint inhibitors in
patients with NSCLC. This combination may be accompanied by important side effects such as pneumonitis [86,87]
and, potentially, myocarditis [88]. However, several retrospective studies showed no increased toxicities for the
combination of immunotherapy and radiotherapy in the treatment of stage IV lung cancer patients [89].
In a prospective study, Formenti et al. tested the combination of radiotherapy with concurrent ipilimumab in 39
patients with metastatic NSCLC and progression after systemic treatment. Only 21 patients were evaluable as 18
patients discontinued ipilimumab treatment, mostly due to the adverse effects of ipilimumab. Of the 21 evaluable
patients, ten presented an abscopal response based on Response Evaluation Criteria in Solid Tumors 1.1 criteria,
using the best responding lesion [90].
In an unplanned secondary analysis of the Phase I KEYNOTE-001 trial, a subgroup of 24 of 97 patients with
metastatic NSCLC receiving thoracic radiotherapy followed by pembrolizumab were analyzed. Pembrolizumab was
associated with significantly longer progression-free survival (PFS) and overall survival in patients who previously
received extracranial radiotherapy compared with those who did not receive extracranial radiotherapy (PFS 6.3
vs 2.0 months; p = 0.008; overall survival 11.6 vs 5.3 months; p = 0.034). Pulmonary toxicity of any grade was
high and of borderline significance (p = 0.052) in patients with previous thoracic radiotherapy (63%, 5/24) versus
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patients with no previous thoracic radiotherapy (40%, 29/73). The incidence of pembrolizumab-related pulmonary
toxicity of any grade was significantly higher in patients with previous thoracic radiotherapy (13%, 3/24) versus
patients with no previous thoracic radiotherapy (1%,1/73; p = 0.046) [91]. Considering that the overall response
rate of single-agent PD-1/PD-L1 blockade is only 17–19%, these data support the use of radiotherapy as a strategy
to induce a response to immune checkpoint inhibitors in patients with metastatic lung cancer [92,93].
This strategy is further supported by the results of a randomized Phase II trial of SBRT and sequential pem-
brolizumab versus pembrolizumab alone for patients with advanced NSCLC. The group treated with radiotherapy
and pembrolizumab showed an overall response rate of 41% and a median PFS of 6.4 months compared with 19%
and 1.8 months, respectively, for the control arm [94].
The PACIFIC trial is a Phase III randomized study comparing durvalumab as consolidation therapy with
placebo in patients with stage III, locally advanced, unresectable NSCLC that had not progressed after platinum-
based chemo-radiotherapy. Immunotherapy increased the 2-year overall survival significantly from 55.6 to 66.3%.
Durvalumab also had a favorable effect on the frequency of new metastases, including a lower incidence of new
brain metastases, and the median time to death or distant metastases was longer in patients treated with durvalumab
(23.2 vs 14.6 months, hazard ratio: 0.52; 95% CI 0.39–0.69; p < 0.001). With regard to safety, the incidence of
adverse events of any cause was similar in the two groups: 96.8% in patients who received durvalumab and 94.9%
in patients who received placebo; grade 3 or 4 adverse events occurred in 29.9 and 26.1%, respectively, and the
most frequent were pneumonia (4% in each arm) and pneumonitis (3% in each arm) [95].
To date, about 40 planned or ongoing trials investigating radiotherapy combined with immune checkpoint
inhibitors in patients with NSCLC are registered at the ClinicalTrials. gov registry.
The recent systematic review of Chicas-Sett et al., investigating the combination of radiotherapy and checkpoint
inhibitors in NSCLC, reported a mean PFS of 4.6 months and a weighted mean overall survival of 12.4 months
in combination therapy. When compared with patients with NSCLC and checkpoint inhibitor therapy only, PFS
was slightly higher in the combination group and overall survival was reported to be similar, especially considering
prospective studies. This questions an additional survival benefit of radiotherapy and immunotherapy together,
even if the abscopal effect is more prevalent in this group. Grade ≥3 toxicity ranged between 10 and 17% for
anti-PD-1/PD-L1 and 29 and 38% for anti-CTLA-4, which is consistent with the adverse events that can be
expected from checkpoint inhibitors alone [8]. These results have to be considered carefully as retrospective and
prospective studies and studies with different cancer types were included in this review.
Conclusion
The abscopal effect of radiotherapy has been reported in preclinical and clinical studies in different tumor entities.
The mechanism responsible for this effect is immune mediated: irradiated tumor cells can, in fact, stimulate
antitumor adaptive immunity by inducing the release of tumor antigens and their cross-presentation to CD8+ T
cells. Only a few cases of the abscopal effect after radiotherapy alone have been reported in patients with lung
cancer so far. However, with the development of immunotherapy, especially of immune checkpoints inhibitors, the
abscopal effect of radiotherapy might become more frequent. Immunotherapy can potentiate the in situ vaccination
effect of radiotherapy.
Future perspective
Many challenges remain for this combined treatment as the optimal dose/fractionation schemes for radiotherapy,
the optimal time of administration of immunotherapy and the prediction of treatment efficacy are still unclear.
These questions need to be addressed in future clinical studies with the aim of developing evidence-based guidelines
for radiotherapy and immunotherapy.
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Executive summary
Immunotherapy & radiotherapy in lung cancer
• Immunotherapy, especially using checkpoint inhibitors, has shown some promise in modulating the tumor
microenvironment, in order to fight against the tumor’s attempt to evade the immune system.
• Radiotherapy plays an important role in lung cancer treatment and is used from early to advanced stages.
Abscopal effect
• The abscopal effect is a rare phenomenon in radiotherapy characterized by tumor regression outside the
irradiated volume.
• The abscopal effect of radiotherapy could be enhanced by combining immunotherapy and radiotherapy.
• The incidence of the abscopal effect has increased over the last decade after the introduction of checkpoint
inhibitors in lung cancer treatment.
Radiation & the immune system
• The mechanism underlying the abscopal effect is immune mediated. Radiotherapy can lead to immunogenic cell
death and the release of tumor antigens by irradiated tumor cells, stimulating an antitumor immune response.
The administration of immune checkpoint inhibitors acting at different points enhances this response.
Timing of immunotherapy in combination with radiotherapy
• Various preclinical and clinical studies have investigated the optimal strategies for combining radiotherapy and
immunotherapy, but timing, dose and fractionation remain unclear.
Clinical trials
• Recent clinical trials support the efficacy and safety of radiotherapy and immunotherapy combination treatment.
Future perspective
• Questions relating to the ideal dose/fractionation schemes for radiotherapy and the optimal timing of
checkpoint inhibitor administration need to be addressed in future clinical studies with the aim of developing
evidence-based guidelines for radiotherapy and immunotherapy.
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